# ADASUVE 2-dose Thorough QT/QTc Study

> **NCT01854710** · PHASE4 · COMPLETED · sponsor: **Alexza Pharmaceuticals, Inc.** · enrollment: 60 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** ADASUVE 10 mg 2 doses 2 hours apart
- **DRUG:** Inhaled Placebo
- **DRUG:** Oral moxifloxacin 400 mg
- **DRUG:** Oral placebo

## Key facts

- **NCT ID:** NCT01854710
- **Lead sponsor:** Alexza Pharmaceuticals, Inc.
- **Sponsor class:** UNKNOWN
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05
- **Primary completion:** 2013-07
- **Final completion:** 2013-07
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2017-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01854710

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01854710, "ADASUVE 2-dose Thorough QT/QTc Study". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT01854710. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*